This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Tirbanibulin topical

Updated 2 Feb 2023 | Photodamaged skin treatments


Topical formulation of tirbanibulin.

Drugs List

  • KLISYRI 10mg/g ointment
  • tirbanibulin 10mg/g ointment
  • Therapeutic Indications


    Treatment of actinic keratoses

    Field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.



    Applied to the affected field on the face or scalp once daily for one treatment cycle of 5 consecutive days.

    A thin layer of ointment should be applied to cover the treatment field of up to 25 centimetres squared.

    Therapeutic effect can be assessed 8 weeks after treatment starts. If the treated area does not show complete clearance at the follow-up examination, about 8 weeks after the treatment cycle started or thereafter, the treatment should be re-evaluated and management re-considered.

    Additional Dosage Information

    Missed dose
    If a dose is missed, the patient should apply the ointment as soon as they remember and then continue with the regular schedule. The ointment should not be applied more than once a day.


    Tirbanibulin is for external use on the face or scalp only.

    Before application, patients should wash the treatment field with mild soap and water and dry it.

    Tirbanibulin should be applied at the same time each day. The treatment area should not be bandaged or otherwise occluded.


    Children under 18 years
    Open wounds

    Precautions and Warnings

    Females of childbearing potential

    Treatment to be initiated and supervised by a specialist
    Contains propylene glycol: may cause irritation
    Avoid application to broken skin
    Avoid contact with ears
    Avoid contact with eyes
    Avoid contact with nostrils or mouth
    Avoid occlusive dressings
    If accidental contact with the eyes occurs, rinse thoroughly with water
    Do not use for longer than 5 consecutive days
    Advise patient not to wash treated area for 8 hours after application
    Advise patient to avoid exposure to sunlight and UV rays during treatment
    Advise patient to wash hands before and after use

    If accidental ingestion occurs, the patient should drink plenty of water and seek medical care.

    Tirbanibulin ointment may cause eye irritation. In the event of accidental contact with the eyes, the eyes should be rinsed immediately with large amounts of water, and the patient should seek medical care as soon as possible.

    Application of tirbanibulin ointment is not recommended until the skin is healed from treatment with any previous medicinal product, procedure or surgical treatment and should not be applied to open wounds or broken skin where the skin barrier is compromised.

    Changes in the appearance of actinic keratosis could suggest progression to invasive squamous cell carcinoma. Clinically atypical lesions for actinic keratosis or suspicious for malignancy should be appropriately managed.

    Pregnancy and Lactation


    Tirbanibulin is contraindicated during pregnancy.

    The manufacturer does not recommend using tirbanibulin during pregnancy. At the time of writing there is no or limited data from the use of tirbanibulin in pregnant women. Animal studies have shown reproductive toxicity.


    Tirbanibulin is contraindicated during breastfeeding.

    The manufacturer advises that the patient either discontinues breastfeeding or discontinues tirbanibulin. It is unknown whether tirbanibulin or its metabolites are excreted in human breast milk. A risk to newborns/infants cannot be excluded.

    Side Effects

    Crusting of skin
    Erythema at application site
    Formation of pustules
    Localised exfoliation
    Pain at application site
    Skin reactions
    Ulceration (application site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2021

    Reference Sources

    Summary of Product Characteristics: Klisyri 10mg/g ointment. Almirall Limited. Revised August 2021.

    NICE Evidence Services Available at: Last accessed: 24 December 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.